Company Overview
About NRG Therapeutics
NRG Therapeutics develops first-in-class oral small molecules targeting the mitochondrial permeability transition pore (mPTP) — a protein complex whose aberrant opening triggers the cellular energy failure and neurodegeneration that underlies ALS (amyotrophic lateral sclerosis) and Parkinson's disease. The company raised £50 million ($67 million) in an oversubscribed Series B in September 2025, and dosed the first clinical trial participants for NRG5051 in January 2026, with Phase 1 readout expected by end of 2026.
Business Model & Competitive Advantage
The mPTP target represents a genuinely new mechanism for neurodegenerative disease: rather than targeting the protein aggregates (tau, alpha-synuclein, TDP-43) that accumulate in neurodegenerative conditions, NRG targets the cellular energy infrastructure failure that these aggregates cause. By stabilizing mPTP function, NRG5051 aims to preserve neuronal energy metabolism that aggregates disrupt — a disease-modifying approach that could apply across multiple neurodegenerative conditions sharing this common pathological mechanism.
Competitive Landscape 2025–2026
The CNS penetrance of NRG5051 is the key pharmacological challenge that makes the oral small molecule approach technically difficult: the blood-brain barrier restricts most compounds from reaching the brain in therapeutic concentrations. NRG's disclosed Phase 1 entry reflects pre-clinical CNS penetrance data that justified regulatory approval for human testing — a hurdle that prevents most mitochondria-targeting compounds from reaching the clinic.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
NRG Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare NRG Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from NRG Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim NRG Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention NRG Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →